Pulmonary Fibrosis News and Research

RSS

Case study examines prescriptions and healthcare use in non-hospitalized COVID-19 recoverers

In a new study published in The Lancet, a team of researchers examined prescription drug and healthcare use after SARS-CoV-2 infection in those who did not require hospital admission.

12 May 2021

Comprehensive "cell atlas" shows how COVID-19 can lead to organ failure and death

Scientists from several hospitals and research centers have shown what happens in individual cells of patients who died of COVID-19. In a study published in Nature, the researchers describe how infected cells from multiple organs exhibited a range of molecular and genomic changes.

3 May 2021

New study reveals mechanisms that result in lethal COVID-19

A new study is drawing the most detailed picture yet of SARS-CoV-2 infection in the lung, revealing mechanisms that result in lethal COVID-19, and may explain long-term complications and show how COVID-19 differs from other infectious diseases.

30 Apr 2021

New range of lung-on-chip technologies represent the vital properties of lung tissue

According to the National Institutes of Health, respiratory viruses are the most frequent cause of disease and death in humans, a fact highlighted by the COVID-19 pandemic. Despite the potential to cause severe disease, over 70% of viral infections remain asymptomatic.

24 Mar 2021

A modified protein mediates development of lung fibrosis after cadmium/carbon black exposure

The triggers and causes of a severe scarring disease of the lungs -- idiopathic pulmonary fibrosis, or IPF -- remain unclear.

18 Mar 2021

New approach may lead to novel treatments for renal fibrosis

Ageing is a common factor in many diseases. So, what if it were possible to treat them by acting on the causes of ageing or, more specifically, by acting on the shortening of telomeres, the structures that protect chromosomes?

16 Mar 2021

Researchers discover new molecular target that could treat idiopathic pulmonary fibrosis

Researchers at the University of Alabama at Birmingham have identified a new molecular target that could potentially treat the deadly, aging-related lung disease idiopathic pulmonary fibrosis (IPF).

10 Mar 2021

Cell surface marker CD47 may allow early diagnosis of severe COVID-19

A new study reports the potential of the cell surface marker, CD47, as a biomarker for hyperinflammation, a characteristic feature of severe COVID-19.

4 Mar 2021

Insilico Medicine discovers novel preclinical candidate to address idiopathic pulmonary fibrosis

Insilico Medicine has demonstrated a breakthrough in Artificial Intelligence ("AI") and drug discovery -- linking together generative chemistry and biology for the first time -- to discover a novel preclinical candidate addressing idiopathic pulmonary fibrosis ("IPF") and be validated with multiple human cell and animal model experiments.

25 Feb 2021

Microfluidic chip and AI-powered automated microscope help measure hemoglobin levels

One of the most performed medical diagnostic tests to ascertain the health of patients is a complete blood count, which typically includes an estimate of the hemoglobin concentration.

24 Feb 2021

Study highlights the epigenetics of life at high altitudes

Humans inhabit an incredible range of environments across the globe, from arid deserts to frozen tundra, tropical rainforests, and some of the highest peaks on Earth.

16 Feb 2021

Could Galectin-3 be a potential biomarker to help identify severe COVID-19 early?

Researchers have measured the galectin-3 levels in the sera of hospitalized patients. They found initial high levels indicate patients will become severely ill, suggesting it could be used as a predictor of severe disease.

10 Feb 2021

Bernese researchers develop a second generation lung-on-chip

The lung is a complex organ whose main function is to exchange gases. It is the largest organ in the human body and plays a key role in the oxygenation of all the organs.

8 Feb 2021

ACE2 agonist C21 relieves respiratory difficulty in COVID-19

A new study describes a pilot study on the efficacy of a molecule called C21, which enhances the activity of the angiotensin-converting enzyme 2 (ACE2), the host cell receptor that facilitates viral entry.

2 Feb 2021

Could spironolactone treat COVID-19-related pneumonia and pulmonary fibrosis?

Researchers have described the potential of the drug spironolactone, a potassium-sparing diuretic, and anti-androgen, in preventing or alleviating the severity of COVID-19 pneumonia, and in preventing pulmonary fibrosis.

27 Jan 2021

A traditional Chinese medicine could help treat COVID‐19 symptoms

A team of researchers in China – at Guangzhou University of Chinese Medicine and Yunnan University of Chinese Medicine – recently explored the therapeutic properties of Yinqiao powder in treating COVID-19 symptoms. Their findings were recently published in Phytotherapy Research.

22 Jan 2021

Owlstone Medical introduces breath biopsy panel for respiratory diseases

Owlstone Medical, the leader in Breath Biopsy® for applications in disease detection, today introduced the Respiratory Diseases Research Use Only Panel.

From Owlstone Medical Ltd 19 Jan 2021

Study finds association between severity of COVID-19 and shorter telomeres

Patients with severe COVID-19 disease have significantly shorter telomeres, according to a study conducted by researchers at the Spanish National Cancer Research Centre in collaboration with the COVID-IFEMA Field Hospital, published in the journal Aging.

11 Jan 2021

BU researchers awarded $2.4 million NIH grant to study idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a serious chronic disease that affects the tissue surrounding the air sacs in the lungs.

17 Dec 2020

New collaborative study to address key questions about COVID-19

A new nationwide study of more than 50,000 individuals is underway to determine factors that predict disease severity and long-term health impacts of COVID-19.

11 Dec 2020